Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 1061 to 1070 of 1100 total matches.

Booster Doses of COVID-19 Vaccines

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
recipients versus 8 in the placebo group. This data analysis was performed in June 2021, before the Delta ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-8 |  Show IntroductionHide Introduction

Drugs for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
. It has been effective in small studies,18,19 but more data are needed. Treatment of individual patients ...
Pediculosis capitis (head lice infestations) occur in all age groups, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact. Pharmacologic treatment is recommended for persons with live lice or eggs (nits) within 1 cm of the scalp. Topical pediculicides should be tried first. Oral therapy is occasionally required for refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92   doi:10.58347/tml.2024.1704a |  Show IntroductionHide Introduction

Lebrikizumab (Ebglyss) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
with prior exacerbations and elevated eosinophil levels,14 but high-quality data are lacking. ADVERSE ...
The FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg). Lebrikizumab is the third subcutaneously injected human IgG4 monoclonal antibody to be approved in the US for this indication. Tralokinumab (Adbry), another IL-13 antagonist, is also approved for use in patients ≥12 years old, and dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81   doi:10.58347/tml.2024.1715b |  Show IntroductionHide Introduction

Drugs for Bacterial Infections

   
Treatment Guidelines from The Medical Letter • Jul 01, 2013  (Issue 131)
S. pneumoniae (levofloxacin or moxifloxacin) is recommended pending culture results.16 Although clinical data ...
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Treat Guidel Med Lett. 2013 Jul;11(131):65-74 |  Show IntroductionHide Introduction

Antithrombotic Drugs

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014  (Issue 1454)
– Iprivask (Marathon) No data 15 mg SC q12h10 3600.0011 Factor Xa Inhibitors Fondaparinux4 – generic 5-10 ...
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Med Lett Drugs Ther. 2014 Oct 27;56(1454):103-8 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
; without cholestyramine, leflunomide can remain detectable in serum for up to 2 years. No data ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
thereafter. Data on the use of DOACs in patients who weigh >120 kg or have a BMI >35 kg/m2 are limited ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Transdermal Rotigotine (Neupro) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007  (Issue 1268)
mg tabs 1. Cost of 30 days’ treatment with the lowest usual dosage based on the most recent data ...
Rotigotine (Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).
Med Lett Drugs Ther. 2007 Aug 27;49(1268):69-70 |  Show IntroductionHide Introduction

Who Should Take Vitamin Supplements?

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
data have become available on the benefits and risks of taking vitamins. VITAMIN E — Vitamin E ...
Many patients ask their healthcare providers whether they should take vitamins. Since the last Medical Letter article on this subject, more data have become available on the benefits and risks of taking vitamins.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):101-3 |  Show IntroductionHide Introduction

Suflave — A Low-Volume Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
with magnesium. PREGNANCY AND LACTATION — No data are available on the use of Suflave in pregnant or lactating ...
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51   doi:10.58347/tml.2023.1685b |  Show IntroductionHide Introduction